GlassScriptPhysician profile
David S Shimm
NPI 1770570731
$5,496.67
in general payments reported to CMS, 2019-2025
64 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $229 · 2021: $14.00 · 2022: $27.21 · 2023: $1,167 · 2024: $1,775 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $616.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $450.33 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $354.03 | 2023-2025 | Enhertu |
| Incyte Corporation | $271.51 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $266.10 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $239.90 | 2019-2025 | Lynparza, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $208.99 | 2019-2025 | |
| Astellas Pharma US INC | $208.74 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Genzyme Corporation | $171.88 | 2019-2025 | |
| Abbvie INC. | $167.64 | 2023-2025 | Venclexta |
| Janssen Biotech, INC. | $158.99 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Glaxosmithkline, LLC. | $149.91 | 2023-2025 | Zejula, Ojjaara |
| Fennec Pharmaceuticals, INC. | $138.66 | 2025 | Fyarro |
| Amgen INC. | $123.01 | 2019-2023 | Kyprolis, Lumakras |
| Seagen INC. | $103.93 | 2019-2023 | Padcev, Tukysa, Adcetris |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $97.98 | 2019-2025 | Polivy, Phesgo, Tecentriq |
| Puma Biotechnology, INC. | $94.31 | 2019-2025 | |
| Eisai INC. | $89.49 | 2023-2025 | |
| Adc Therapeutics America, INC. | $72.53 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $71.16 | 2019-2020 | |
| Pfizer INC. | $69.64 | 2024-2025 | |
| Coherus Oncology, INC. | $68.40 | 2023-2025 | Loqtorzi, Udenyca |
| Karyopharm Therapeutics INC. | $68.05 | 2023-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $61.13 | 2024-2025 | Ninlaro, Alunbrig |
| Beigene USA, INC. | $59.80 | 2023-2024 | Tevimbra, Brukinsa |
| Celgene Corporation | $57.58 | 2019-2023 | Reblozyl |
| Blueprint Medicines Corporation | $49.60 | 2023-2024 | Ayvakit |
| Taiho Oncology, INC. | $49.29 | 2023-2025 | |
| Mirati Therapeutics, INC. | $45.88 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $44.66 | 2022-2023 | Imbruvica, Epkinly |
| Geron Corporation | $42.80 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $42.52 | 2025 | Tevimbra, Brukinsa |
| Gilead Sciences, INC. | $41.20 | 2024-2025 | Trodelvy |
| Adaptive Biotechnologies Corporation | $40.79 | 2024-2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $40.66 | 2019-2024 | Ultomiris |
| Tersera Therapeutics LLC | $40.38 | 2024-2025 | Xermelo, Quzyttir |
| Tesaro, INC. | $33.32 | 2019 | |
| Cti Biopharma Corp. | $31.13 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $29.37 | 2023-2025 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $28.78 | 2024 | Givlaari |
| Agios Pharmaceuticals, INC. | $28.47 | 2019-2025 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $27.98 | 2025 | Revuforj |
| Ipsen Biopharmaceuticals, INC | $26.62 | 2019-2024 | Onivyde, Somatuline Depot |
| Aveo Pharmaceuticals, INC. | $26.35 | 2023-2024 | Fotivda |
| Kyowa Kirin, INC. | $26.23 | 2024 | Poteligeo |
| Springworks Therapeutics, INC. | $25.53 | 2024 | Ogsiveo |
| Progenics Pharmaceuticals, INC. | $24.45 | 2024 | |
| Servier Pharmaceuticals LLC | $24.38 | 2024 | |
| Emd Serono, INC. | $23.82 | 2019 | |
| Iovance Biotherapeutics, INC. | $23.18 | 2025 | Amtagvi |
| Telix Pharmaceuticals | $22.86 | 2025 | Illuccix |
| Sobi, INC | $21.67 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.01 | 2023 | Libtayo |
| Novocure INC. | $20.16 | 2023 | Optune |
| Exelixis INC. | $18.33 | 2019 | |
| Foundation Medicine, INC. | $17.97 | 2020 | |
| Stemline Therapeutics INC. | $17.73 | 2025 | Orserdu |
| Curium US LLC | $17.50 | 2024 | Detectnet |
| Array Biopharma INC | $16.51 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.28 | 2023 | Tavalisse, Rezlidhia |
| Sanofi-Aventis U.S. LLC | $14.63 | 2019 | |
| Myovant Sciences INC. | $14.24 | 2022 | |
| Accuray Incorporated | $14.00 | 2021 | |
| Clovis Oncology, INC. | $7.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.